Psyence BioMed unit signs term sheet for exclusive US ibogaine license, supply deal with PsyLabs
Bitget2026/09/28 11:02- Psyence Biomedical’s Texas unit TIRC signed a binding term sheet for an exclusive U.S. license to PsyLabs’ pharmaceutical-grade ibogaine.
- Definitive agreement targeted by Nov. 30, 2026; term sheet lapses if no deal is signed by that date.
- Arrangement includes exclusive U.S. supply from PsyLabs, with TIRC as exclusive U.S. wholesaler and distributor.
- Economics include up to about USD 1.3 million in development and regulatory milestones for the first drug candidate.
- Also includes an annual exclusivity fee starting after first FDA approval, plus low single-digit royalties on net sales.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The Federal Reserve Eyes $1.8 Trillion in “Shadow Credit”: Dallas and New York Fed Launch First Private Credit Survey
The Dallas and New York Federal Reserves have launched an investigation into private credit lending standards, covering an industry worth 1.8 trillions USD, with a minimum threshold of 50 millions USD. The results will be released in the first quarter of 2027.
Tom Lee Says a VIX Signal Points to a Stock Market Bottom
Is AI an engine or a killer? Morgan Stanley provides answers with data: productivity soars, but nearly 90% of the benefits are taken by 12 industries
Morgan Stanley stated that the productivity dividends from AI are concentrated in 12 highly exposed industries, with growth rates reaching twice the twenty-year average. For the first time, signs of job replacement have emerged.
Crypto prices
More
